Bispecific antibodies for the treatment of haemophilia A.
Sign Up to like & getrecommendations! Published in 2021 at "Expert opinion on biological therapy"
DOI: 10.1080/14712598.2021.1940133
Abstract: INTRODUCTION : Emicizumab is a bispecific antibody exerting cofactor function of FVIIIa irrespective of the presence of FVIII inhibitors. Long-term data of phase 1/2 and phase 3 studies have been accumulated. Various questions such as… read more here.
Keywords: treatment; antibodies treatment; treatment haemophilia; bispecific antibodies ... See more keywords